RPRDx is a leading brand in the field of pharmacogenomics (PGx), offering high-quality solutions that are backed by strong scientific evidence and powered by the latest innovations. Their primary goal is to enable precision medicine and improve patient care outcomes. Their comprehensive range of products and services includes the Whole Pharmacogenomics Scan (WPS®), Precision HealthPGx Panel, Psych HealthPGx Panel, CYP2D6 Genotyping, CYP2C19 Rapid Genotyping, and Next Generation Sequencing Custom Panel.

These tests provide actionable clinical results for patients of all races and ethnicities, ensuring inclusive care. RPRDx's scientific team, with over 20 years of genomics research experience, collaborates with renowned institutions like St Jude Children's Research Hospital and Harvard Medical School to advance PGx clinical implementations. Their expertise, coupled with advanced technologies, empowers clinicians to provide personalized therapies and improve patient outcomes.

With a focus on evidence-based and high-quality solutions, RPRDx is committed to accelerating personalized therapies and bringing pharmacogenetics into the mainstream. Partnering with them means gaining access to the most comprehensive PGx testing, leading research, and a commitment to advancing the field for better care tomorrow